Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Osteoporosis medications such as bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab can slow jaw bone healing and, in rare cases, contribute to medication-related osteonecrosis of the jaw (MRONJ), so your dentist and your prescribing doctor should both be told before any extraction, implant, or bone-related oral surgery. Safer planning typically involves a pre-surgical dental exam and cleaning, clearing infections and gum disease first, choosing the least invasive procedure possible, coordinating timing with your dosing schedule, and considering a temporary pause in medication only when your prescriber agrees it is appropriate. Your personal risk level varies with how long you have taken the drug, whether it was oral or intravenous, steroid use, diabetes, smoking, and whether the dose was for osteoporosis or cancer, and there are several important factors to weigh. See below to understand more, including warning signs like exposed bone, jaw pain, swelling, or a socket that will not heal.
If you are dealing with jaw pain, gum swelling, a loose tooth, or slow healing after dental work, a free, instant, online symptom check can help you sort out what may be happening and how urgently it should be evaluated. It takes only a few minutes, is available any time, and gives you clear, personalized guid
If you’re taking medications for osteoporosis—such as bisphosphonates (alendronate, risedronate) or denosumab—to strengthen your bones, you may face a rare but serious complication called osteonecrosis of the jaw. This condition can develop after dental extraction or other oral surgeries. With careful planning and clear communication between you, your dentist, and your medical team, you can minimize risks and protect your oral health.
Osteonecrosis of the jaw (ONJ) happens when bone in the jaw fails to heal after minor trauma—like a tooth extraction—leading to exposed bone, pain, and possible infection. Although uncommon, ONJ can be challenging to treat and often requires long courses of antibiotics, surgical debridement, or other interventions.
Key facts about ONJ:
Medications that slow bone turnover help prevent fractures but can also delay bone healing. During an extraction or other surgeries, delayed healing increases the risk of osteonecrosis of the jaw. To keep the risk low, follow these guidelines:
Before scheduling oral surgery, coordinate with both your dentist and the physician managing your osteoporosis meds:
A detailed evaluation helps your care team decide if any adjustments—such as a temporary “drug holiday”—are appropriate. Always balance fracture risk against ONJ risk. Do NOT stop medications on your own.
Drug Holidays
A drug holiday means temporarily pausing osteoporosis medications around the time of surgery. It may lower ONJ risk by allowing normal bone turnover to resume.
Antibiotic Prophylaxis
Your dentist may prescribe antibiotics before, during, and after surgery to prevent infection and promote healing. Common choices include amoxicillin or clindamycin (for penicillin-allergic patients).
Local Measures
Choosing a minimally traumatic approach and adhering to careful aftercare protocols are central to reducing ONJ risk.
Key surgical considerations:
Post-operative instructions:
Even with perfect planning, complications can occur. Early recognition of any trouble allows prompt treatment and better outcomes.
Watch for:
If any of these symptoms appear, reach out to your dentist or physician immediately. For a quick assessment of new or concerning symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Beyond surgical planning, maintaining strong overall health supports good healing:
• Osteonecrosis of the jaw (ONJ) is rare but serious when it follows dental surgery in patients on osteoporosis meds.
• Coordinate closely with your dentist and medical doctor on pre-operative evaluation, medication timing, and antibiotic prophylaxis.
• Gentle surgical techniques and meticulous aftercare—soft diet, antiseptic rinses, no smoking—help prevent complications.
• Monitor healing closely and report any pain, swelling, or exposed bone without delay.
• Use tools like the free, online symptom check, using the doctor approved Ubie Symptom Checker to guide next steps.
Always remember: your health is a team effort. Talk through any concerns or questions with your dental and medical providers before surgery.
If you experience any life-threatening or serious symptoms—such as severe pain, extensive swelling, fever, difficulty breathing, or uncontrolled bleeding—seek emergency care right away.
Speak to a doctor about anything that could be life threatening or serious.
(References)
* Dioguardi M, Di Cosola M, Copelli C, Cantore S, Quarta C, Nitsch G, Sovereto D, Spirito F, Caloro GA, Cazzolla AP, Aiuto R, Cascardi E, Greco Lucchina A, Lo Muzio L, Ballini A, Mastrangelo F. Oral bisphosphonate-induced osteonecrosis complications in patients undergoing tooth extraction: a systematic review and literature updates. Eur Rev Med Pharmacol Sci. 2023 Jul;27(13):6359-6373. doi: 10.26355/eurrev_202307_32996. PMID: 37458653.
* Goss AN. Bisphosphonates and orthodontics. Aust Orthod J. 2008 May;24(1):56-7. PMID: 18649566.
* van Nuijs T. [Bisphosphonates]. Rev Belge Med Dent (1984). 2007;62(4):151. PMID: 18506989.
* Park JH, Kong SH, Lee J, Oh J, Lee JR, Lee HJ, Kim JW. Time since last intravenous bisphosphonate and risk of osteonecrosis of the jaw in osteoporotic patients. Nat Commun. 2025 May 11;16(1):4367. doi: 10.1038/s41467-025-59718-x. Epub 2025 May 11. PMID: 40350503; PMCID: PMC12066712.
* Eleutherakis-Papaiakovou E, Bamias A. Antiresorptive treatment-associated ONJ. Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12787. Epub 2017 Oct 24. PMID: 29063702.
* McCaul JA. Pharmacologic modalities in the treatment of osteoradionecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2014 May;26(2):247-52. doi: 10.1016/j.coms.2014.02.002. PMID: 24794269.
* Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis. 2008 Apr;14(3):277-85. doi: 10.1111/j.1601-0825.2007.01381.x. PMID: 18336375.
* Kraut RA. Current therapy: a moving target. Implant Dent. 2009 Feb;18(1):1-2. doi: 10.1097/ID.0b013e31819b0b3e. PMID: 19212230.
* Hadaya D, Soundia A, Gkouveris I, Bezouglaia O, Dry SM, Pirih FQ, Aghaloo TL, Tetradis S. Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden. J Dent Res. 2021 Jul;100(7):746-753. doi: 10.1177/0022034520986804. Epub 2021 Jan 21. PMID: 33478337; PMCID: PMC8221704.
* Ritter AV, Padilla R. Bisphosphonates and oral health. J Esthet Restor Dent. 2008;20(1):74-5. doi: 10.1111/j.1708-8240.2008.00152.x. PMID: 18237344.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.